Determinants of hypertension following pregnancy - project description
Cardiovascular diseases (CVD) are the leading causes of death in women and hypertension is one of the most important modifiable risk factors for CVD. The project evaluates lifestyle characteristics and hypertension disorders of pregnancy as determinants of chronic hypertension. The project utilizes the Norwegian Mother and Child Cohort (MoBa) with linkages to the Norwegian Medical Birth Registry for ascertainment of pregnancy-related complications and outcomes. Further, linkages to the National Prescription Database provide information on the use of anti-hypertensive medications following pregnancy. The project will contribute to our understanding of the life-course epidemiology of cardiovascular disease in women and guide in the development of relevant intervention strategies. Further, with Regional Ethics Committee approvals in the fall of 2017, the project was expanded to include diabetes mellitus as an outcome utilizing the same data material.
See the full project description at Cristin for more information about results, researchers, contact information etc.
Svetlana Skurtveit, Avdeling for psykiske lidelser, Norwegian Institute of Public Health
Anne Lise Brantsæter, Avdeling for miljøeksponering og -epidemiologi, Norwegian Institute of Public Health
Lill-Iren Schou Trogstad, Avdeling for infeksjonsepidemiologi og modellering, Norwegian Institute of Public Health
Anne Cathrine Staff, Division of Gynaecology and Obstetrics, University of Oslo
Per Magnus, Senter for fruktbarhet og helse, Norwegian Institute of Public Health
Alice Margareta Haugen, Avdeling for miljøeksponering og -epidemiologi, Norwegian Institute of Public Health
Jannike Øyen, Seafood in model systems, Institute of Marine Research
Bjørn Egil Vikse, Medisinsk avdeling, Bergen Hospital Trust - Haukeland University Hospital
Kari Klungsøyr, Avdeling for helsefremmende arbeid, Norwegian Institute of Public Health
Geir Egil Eide, Institutt for global helse og samfunnsmedisin, University of Bergen
Anne Kjersti Daltveit, Institutt for global helse og samfunnsmedisin, University of Bergen
Solveig Sakshaug, Avdeling for legemiddelstatistikk, Norwegian Institute of Public Health
Jutta Dierkes, Klinisk institutt 1, University of Bergen